Glatiramer acetate

Medication used to treat multiple sclerosis

Glatiramer acetate

Glatiramer acetate is a medication used in the treatment of multiple sclerosis (MS), specifically for reducing the frequency of relapses in patients with relapsing-remitting multiple sclerosis (RRMS). It is marketed under the brand name Copaxone.

Mechanism of Action

Glatiramer acetate is a mixture of synthetic polypeptides composed of four amino acids: L-glutamic acid, L-lysine, L-alanine, and L-tyrosine. The exact mechanism by which glatiramer acetate exerts its effects in MS is not fully understood. However, it is believed to act by modifying immune processes that are thought to be responsible for the pathogenesis of MS. It is thought to induce a shift from a pro-inflammatory T-helper 1 (Th1) response to an anti-inflammatory T-helper 2 (Th2) response, thereby reducing inflammation and demyelination in the central nervous system.

Administration

Glatiramer acetate is administered by subcutaneous injection. The standard dosage is 20 mg per day or 40 mg three times a week, depending on the specific formulation prescribed. Patients are instructed to rotate injection sites to minimize the risk of injection site reactions.

Injection site reaction from Copaxone

Side Effects

Common side effects of glatiramer acetate include injection site reactions, such as redness, pain, swelling, and itching. Systemic reactions may also occur, including flushing, chest pain, palpitations, anxiety, and shortness of breath. These systemic reactions are usually transient and resolve without treatment.

Clinical Use

Glatiramer acetate is primarily used in the management of relapsing forms of multiple sclerosis. It has been shown to reduce the frequency of clinical exacerbations and slow the progression of disability in patients with RRMS. It is not a cure for MS but helps manage symptoms and reduce the frequency of relapses.

History

Glatiramer acetate was developed in the 1960s by researchers at the Weizmann Institute of Science in Israel. It was initially intended as a model compound to induce experimental autoimmune encephalomyelitis (EAE), an animal model of MS. However, it was found to have a protective effect against EAE, leading to its development as a treatment for MS. It was approved for medical use in the United States in 1996.

Related Pages

• Multiple sclerosis
• Relapsing-remitting multiple sclerosis
• Immunomodulation